By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website –
Check out our openings –

Key Statistics

Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN



Sanofi US 


Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 

Company News
Regeneron (REGN) CEO Says Critique of the Company's New Cholesterol Lowering Therapy Was Non-Scientific 5/13/2016 6:25:42 AM
Eli Lilly (LLY) and Regeneron (REGN): How to Find Your First Biopharma Job Right Out of College 5/9/2016 2:06:13 PM
Regeneron (REGN) Reports First Quarter 2016 Financial And Operating Results 5/5/2016 7:24:23 AM
Regeneron (REGN)'s Pain Drug Fasinumab Meets Goals in Late Stage Study 5/2/2016 5:51:26 AM
Regeneron (REGN) Announces Upcoming 2016 Investor Conference Presentations 4/29/2016 8:29:18 AM
Biogen (BIIB), Regeneron (REGN) and Valeant (VRX) Rank High as Potential Takeover Targets for Allergan (AGN) 4/21/2016 7:27:42 AM
3 Biotech Stocks to Withstand the Presidential Race 4/20/2016 8:02:35 AM
Regeneron (REGN) To Report First Quarter 2016 Financial And Operating Results And Host Conference Call And Webcast On May 5, 2016 4/15/2016 8:41:24 AM
In a Volatile Biotech Market, Here are 3 Stocks To Consider 4/12/2016 7:08:48 AM
Bay States's Intellia Discloses a $125 Million CRISPR/Cas Deal with Regeneron (REGN) and Files for $120 Million IPO 4/12/2016 6:10:07 AM